This Could Help You Overcome Treatment-Resistant Depression

Road splitting at a cliff with signs pointing to suicide and support
Photo: Lightspring / Shutterstock

A small but carefully controlled study found that a single high dose of psilocybin eased one of depression’s cruelest symptoms: the inability to feel pleasure.

Quick Take

  • Twenty adults with treatment-resistant depression took part in a randomized, double-blind trial comparing 25 mg of psilocybin to a 1 mg control dose.
  • The 25 mg group showed a significant improvement on a pleasure-tracking scale by week eight, though early results were mixed.
  • Researchers used specific tools, including the Dimensional Anhedonia Rating Scale, to measure loss of pleasure separately from overall depression symptoms.
  • The trial is a pilot study, meaning its small size calls for larger follow-up research before firm conclusions can be drawn.

What The Trial Actually Tested

Doctors call it anhedonia. It is the flat, gray feeling that takes the joy out of a favorite meal, a grandchild’s laugh, or a morning walk. It is one of the toughest parts of depression to treat, and standard antidepressants often fail to touch it. This new trial zeroed in on that exact symptom instead of just measuring overall sadness scores.

Researchers recruited 20 adults with treatment-resistant major depressive disorder, meaning standard treatments had already let them down. Participants were randomly split into two groups. One received a 25 mg dose of psilocybin, the active compound in certain mushrooms. The other received a nearly inactive 1 mg dose. Neither the participants nor the research team knew who got which dose during the trial.

The primary measuring tool was the Dimensional Anhedonia Rating Scale, known as DARS, which tracks a person’s ability to enjoy hobbies, food, social time, and sensory experiences. Researchers also used two backup scales, the Snaith-Hamilton Pleasure Scale and the Montgomery-Asberg Depression Rating Scale, to cross-check the findings across different angles of mood and pleasure.

Mixed Early Signs, Stronger Later Results

At the one-week mark, the gap between the two groups was too small to call meaningful. That is an honest early finding, not a failure. Depression treatments often take time to show their full effect, and a single data point rarely tells the whole story.

By week eight, the picture changed. The group that received the full 25 mg dose showed a statistically significant improvement on a secondary DARS measurement compared to the low-dose group. Researchers at the University of Colorado Anschutz Medical Campus, who helped lead the work, described the finding as meaningful progress on a symptom that has frustrated patients and doctors alike for decades.

Other published psilocybin research backs up the general pattern. A broader review of anhedonia studies found consistent reductions in that symptom when measured through tools like SHAPS and MADRS across multiple psilocybin trials for both unipolar and bipolar depression. That consistency matters. One study showing a result could be a fluke. A pattern across several studies is harder to wave away.

Why This Deserves Careful Optimism, Not Hype

Twenty participants is a small group. Pilot trials like this one exist to test whether a bigger, more expensive study is worth running, not to settle the science for good. Earlier open-label psilocybin research for treatment-resistant depression reported strong results too, but those studies lacked the blinding that protects against people simply feeling better because they expected to.

That tension runs through the entire field. A separate trial comparing psilocybin directly against the common antidepressant escitalopram found both treatments lowered depression scores, with psilocybin showing a modestly larger drop that did not reach statistical significance on every measure. Readers should see these findings for what they are: encouraging, specific, and still early. Nobody in this research is claiming a miracle cure, and that restraint is exactly what makes the result worth taking seriously. Patients battling treatment-resistant depression have waited a long time for anything that moves the needle on anhedonia specifically, and a properly blinded, placebo-controlled trial finding a real signal is a meaningful step forward, even while bigger trials still need to confirm it.

Sources:

mindbodygreen.com, imperial.ac.uk, kclpure.kcl.ac.uk, nejm.org, news.cuanschutz.edu